The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry of HRS-9815 for PET/CT imaging in adult patients with prostate cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
HRS-9815 injection
Incidence and severity of AEs and SAEs,
Time frame: up to 30 days follow-up
Maximum plasma concentration (Cmax)
Time frame: up to 1 days follow-up
time to maximum plasma concentration (Tmax)
Time frame: up to 1 days follow-up
biological half-life (t1/2)
Time frame: up to 1 days follow-up
cumulative urinary excretion rate based on radioactivity;
Time frame: up to 1 days follow-up
Absorbed dose and effective dose of radioactive internal irradiation of the whole body and major organs;
Time frame: up to 1 days follow-up
Mean standardized uptake value (SUVmean)
Time frame: up to 1 days follow-up
Maximum standardized uptake value (SUVmax),
Time frame: up to 1 days follow-up
Tumor-to-background ratio (TBR) [Time Frame: up to 1 days follow-up]
Time frame: up to 1 days follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.